| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$33.4M | ROE | −244.16% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $38.5M | Trading Days | 2717 |
| 52W High | 1.55 |
| 52W Low | 0.51 |
| % Off High | −55.45% |
| YTD | −10.31% | 1Y | −41.47% |
| 3Y | −87.28% | 5Y | −93.17% |
| 10Y | −99.65% | Since incept. (ann.) | −42.16% |
| Ann. Volatility (1Y) | 97.26% | Ann. Volatility (3Y) | 86.97% |
| Sharpe (1Y) | −0.08 | Sharpe (3Y) | −0.33 |
| Max Drawdown (1Y) | −58.73% | Max Drawdown (3Y) | −91.86% |
| Beta (3Y, vs SPY) | 2.43 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| HYPD | HYPERION DEFI, INC. | $36.7M | — |
| GRCE | Grace Therapeutics, Inc. | $36.6M | — |
| RNXT | RenovoRx, Inc. | $40.9M | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $35.3M | — |
| NNVC | NANOVIRICIDES, INC. | $34.9M | — |
| FLNA | FILANA THERAPEUTICS, INC. | $42.7M | — |
| EDSA | Edesa Biotech, Inc. | $44.2M | — |
| LITS | Lite Strategy, Inc. | $33.0M | — |
| MCRB | Seres Therapeutics, Inc. | $46.0M | 7.5 |
| BHST | BIOHARVEST SCIENCES INC. | $46.2M | — |
| IBO | IMPACT BIOMEDICAL INC. | $46.4M |
| TCRT | Alaunos Therapeutics, Inc. | $46.4M | — |
